Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Pyxis Oncology Inc (PYXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/26/2026: PYXS (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.92
1 Year Target Price $6.92
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 94.64M USD | Price to earnings Ratio - | 1Y Target Price 6.92 |
Price to earnings Ratio - | 1Y Target Price 6.92 | ||
Volume (30-day avg) 7 | Beta 1.46 | 52 Weeks Range 0.83 - 5.55 | Updated Date 02/26/2026 |
52 Weeks Range 0.83 - 5.55 | Updated Date 02/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2930.25% |
Management Effectiveness
Return on Assets (TTM) -34.33% | Return on Equity (TTM) -87.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70058803 | Price to Sales(TTM) 33.56 |
Enterprise Value 70058803 | Price to Sales(TTM) 33.56 | ||
Enterprise Value to Revenue 24.84 | Enterprise Value to EBITDA 1.09 | Shares Outstanding 62264215 | Shares Floating 39828550 |
Shares Outstanding 62264215 | Shares Floating 39828550 | ||
Percent Insiders 22.66 | Percent Institutions 37.89 |
Upturn AI SWOT
Pyxis Oncology Inc
Company Overview
History and Background
Pyxis Oncology Inc. was founded in 2019 as a clinical-stage biotechnology company. It focuses on developing antibody-drug conjugates (ADCs) for cancer treatment. The company has advanced its lead candidates through preclinical development and into clinical trials. Pyxis Oncology's evolution has been driven by its strategy to leverage its ADC platform to create innovative therapies for difficult-to-treat cancers. Significant milestones include the initiation of clinical trials for its lead programs and strategic partnerships.
Core Business Areas
- Oncology Therapeutics Development: Pyxis Oncology is dedicated to the discovery, development, and commercialization of novel antibody-drug conjugates (ADCs) for the treatment of various cancers. Their platform aims to create targeted therapies that deliver potent cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues.
Leadership and Structure
Pyxis Oncology Inc. is led by a management team with experience in drug development and the biotechnology industry. The organizational structure is typical of a clinical-stage biotech company, with functional departments for research and development, clinical operations, regulatory affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- PYX-101: A novel ADC targeting a specific antigen expressed on certain types of cancer cells. Currently in clinical development. Competitors in the ADC space include companies like Seagen (now part of Pfizer), Genmab, and AbbVie.
- PYX-201: Another ADC candidate in the company's pipeline, also designed for cancer treatment. Specific targets and indications are still in development. Competitors are similar to those for PYX-101.
Market Dynamics
Industry Overview
The oncology market, particularly the field of targeted therapies and antibody-drug conjugates (ADCs), is a rapidly growing and highly competitive sector. Advances in understanding cancer biology and the development of novel drug delivery systems are driving innovation. The demand for more effective and less toxic cancer treatments remains high.
Positioning
Pyxis Oncology is positioned as a clinical-stage biotechnology company focused on leveraging ADC technology to address unmet needs in oncology. Its competitive advantage lies in its proprietary ADC platform, which aims to create differentiated therapies. However, as a clinical-stage company, it faces the inherent risks associated with drug development.
Total Addressable Market (TAM)
The Total Addressable Market for oncology drugs is vast and continues to expand, with ADCs representing a significant and growing segment. While specific TAM figures for Pyxis Oncology's pipeline candidates are not publicly disclosed, the broader oncology market is valued in hundreds of billions of dollars globally. Pyxis Oncology aims to capture a share of this market by developing novel therapies for specific cancer indications.
Upturn SWOT Analysis
Strengths
- Proprietary ADC platform with potential for novel drug development.
- Focus on a high-growth area within oncology (ADCs).
- Experienced management team (presumed based on industry norms for biotech).
Weaknesses
- Clinical-stage company with no approved products, leading to significant development risk.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
- Lack of established commercial infrastructure.
Opportunities
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancements in cancer research that could validate target antigens.
- Growing market demand for targeted cancer therapies.
- Expansion of the ADC therapeutic class.
Threats
- Failure of clinical trials leading to discontinuation of programs.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Regulatory hurdles and delays in drug approval.
- Changes in healthcare reimbursement policies.
- Patent challenges and intellectual property disputes.
Competitors and Market Share
Key Competitors
- Seagen Inc. (SGEN)
- Genmab A/S (GMAB)
- AbbVie Inc. (ABBV)
Competitive Landscape
Pyxis Oncology faces strong competition in the ADC space from established players with approved products and significant resources. Its primary disadvantage is its clinical-stage status and lack of commercialized products. Its advantage lies in its novel ADC technology and the potential to develop differentiated therapies for unmet needs.
Growth Trajectory and Initiatives
Historical Growth: Pyxis Oncology's historical growth has been characterized by the progression of its R&D pipeline, from initial discovery and preclinical work to early-stage clinical trials. This growth is measured by scientific milestones and the expansion of its clinical programs.
Future Projections: Future projections for Pyxis Oncology are contingent on the success of its ongoing and future clinical trials. Analyst estimates, if available, would focus on potential market penetration of its lead candidates and future revenue streams upon potential commercialization.
Recent Initiatives: Recent initiatives likely include the advancement of its lead ADC candidates into later-stage clinical trials, potential strategic partnerships for co-development or commercialization, and ongoing efforts to expand its pipeline through internal research or acquisitions.
Summary
Pyxis Oncology Inc. is a clinical-stage biotech focused on innovative antibody-drug conjugates for cancer. While it possesses a promising platform and targets a significant market, it faces substantial risks due to its early development stage and intense competition. Success hinges on positive clinical trial outcomes and strategic partnerships. The company needs to carefully manage its cash burn and demonstrate clear clinical differentiation to attract investment and achieve commercial viability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry research reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Stock market investments are subject to risk, and past performance is not indicative of future results. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pyxis Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-08 | Interim CEO & Director Mr. Thomas Civik | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.pyxisoncology.com |
Full time employees 44 | Website https://www.pyxisoncology.com | ||
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.